ENTRY       D00287                      Drug
NAME        Cyclophosphamide (USP);
            Cyclophosphamide hydrate (JP18);
            Cytoxan (TN);
            Neosar (TN)
PRODUCT     CYCLOPHOSPHAMIDE (Athenex Pharmaceutical Division)
            CYCLOPHOSPHAMIDE (AuroMedics Pharma LLC)
            CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation)
            CYCLOPHOSPHAMIDE (Dr. Reddy's Laboratories)
            CYCLOPHOSPHAMIDE (Golden State Medical Supply)
            CYCLOPHOSPHAMIDE (Ingenus Pharmaceuticals)
            CYCLOPHOSPHAMIDE (West-Ward Pharmaceuticals Corp.)
  GENERIC   CYCLOPHOSPHAMIDE (Alembic Pharmaceuticals Limited)
            CYCLOPHOSPHAMIDE (Alembic Pharmaceuticals)
            CYCLOPHOSPHAMIDE (Amneal Pharmaceuticals LLC)
            CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation)
            CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation)
            CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation)
            CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation)
            CYCLOPHOSPHAMIDE (BluePoint Laboratories)
            CYCLOPHOSPHAMIDE (Cipla USA)
            CYCLOPHOSPHAMIDE (Civica)
            CYCLOPHOSPHAMIDE (NorthStar Rx LLC)
            CYCLOPHOSPHAMIDE (NorthStar RxLLC)
            CYCLOPHOSPHAMIDE (STI Pharma LLC)
            CYCLOPHOSPHAMIDE (Sandoz)
FORMULA     C7H15Cl2N2O2P. H2O
EXACT_MASS  278.0354
MOL_WEIGHT  279.1012
CLASS       Antineoplastic
             DG01677  Alkylating agent
              DG01678  Nitrogen mustard analog
               DG01720  Isophosphoramide mustard analog
            Metabolizing enzyme substrate
             DG01638  CYP2A6 substrate
             DG02919  CYP2B6 substrate
             DG02918  CYP2C8 substrate
             DG01642  CYP2C9 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Same as: C06933
            Therapeutic category: 4211
            ATC code: L01AA01
            Chemical structure group: DG00675
            Product (DG00675): D00287<JP/US>
EFFICACY    Antineoplastic, Alkylating agent, Immunosuppressant
  DISEASE   Hodgkin's disease [DS:H00007]
            Burkitt lymphoma [DS:H00008]
            Multiple myeloma [DS:H00010]
            Chronic lymphocytic leukemia [DS:H00005]
            Acute myelogenous leukemia [DS:H00003]
            Acute lymphoblastic (stem-cell) leukemia [DS:H00001 H00002]
            Mycosis fungoides [DS:H01463]
            Neuroblastoma [DS:H00043]
            Adenocarcinoma of the ovary [DS:H00027]
            Retinoblastoma [DS:H01513]
            Carcinoma of the breast [DS:H00031]
            Nephrotic syndrome [DS:H01657]
COMMENT     Active form of prodrug: 4-Hydroxycyclophosphamide [CPD:C07643]
TARGET      DNA
METABOLISM  Enzyme: CYP2B6 [HSA:1555]; CYP2A6 [HSA:1548], CYP2C8 [HSA:1558], CYP2C9 [HSA:1559], CYP3A4 [HSA:1576]
INTERACTION  
STR_MAP     map07040  Antineoplastics - alkylating agents
            map07046  Immunosuppressive agents
            map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01A ALKYLATING AGENTS
                L01AA Nitrogen mustard analogues
                 L01AA01 Cyclophosphamide
                  D00287  Cyclophosphamide (USP) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Alkylating Agents
               Cyclophosphamide
                D00287  Cyclophosphamide (USP)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               421  Alkylating agents
                4211  Chlorethylamines
                 D00287  Cyclophosphamide (USP); Cyclophosphamide hydrate (JP18)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01677  Alkylating agent
               DG01678  Nitrogen mustard analog
                DG01720  Isophosphoramide mustard analog
                 DG00675  Cyclophosphamide
                  D00287  Cyclophosphamide
             Metabolizing enzyme substrate
              DG01638  CYP2A6 substrate
               DG00675  Cyclophosphamide
                D00287  Cyclophosphamide
              DG02919  CYP2B6 substrate
               DG00675  Cyclophosphamide
                D00287  Cyclophosphamide
              DG02918  CYP2C8 substrate
               DG00675  Cyclophosphamide
                D00287  Cyclophosphamide
              DG01642  CYP2C9 substrate
               DG00675  Cyclophosphamide
                D00287  Cyclophosphamide
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00675  Cyclophosphamide
                 D00287  Cyclophosphamide
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00287  Cyclophosphamide hydrate
              D00287  Cyclophosphamide tablets
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00287
            Drug groups [BR:br08330]
             Antineoplastic
              DG01677  Alkylating agent
               DG01678  Nitrogen mustard analog
                DG01720  Isophosphoramide mustard analog
                 DG00675  Cyclophosphamide
             Metabolizing enzyme substrate
              DG01638  CYP2A6 substrate
               DG00675  Cyclophosphamide
              DG02919  CYP2B6 substrate
               DG00675  Cyclophosphamide
              DG02918  CYP2C8 substrate
               DG00675  Cyclophosphamide
              DG01642  CYP2C9 substrate
               DG00675  Cyclophosphamide
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00675  Cyclophosphamide
            Prodrugs [br08324.html(DG00675)]
             DG00675
DBLINKS     CAS: 6055-19-2
            PubChem: 7847353
            ChEBI: 4026
            LigandBox: D00287
            NIKKAJI: J237.741A
ATOM        15
            1   P1a P    22.9658  -14.9801
            2   N1c N    22.9715  -13.5156
            3   N1x N    24.0976  -15.6395
            4   O2x O    21.8279  -15.6395
            5   O3b O    21.6997  -14.2450
            6   C1b C    21.6646  -12.8388
            7   C1b C    24.2027  -12.7220
            8   C1x C    24.0976  -16.9523
            9   C1x C    21.8279  -16.9523
            10  C1b C    20.4335  -13.6264
            11  C1b C    25.5096  -13.3990
            12  C1x C    22.9658  -17.5999
            13  X   Cl   19.1265  -12.9613
            14  X   Cl   26.7467  -12.6054
            15  O0  O    27.7975  -15.3471
BOND        14
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     1   5 2
            5     2   6 1
            6     2   7 1
            7     3   8 1
            8     4   9 1
            9     6  10 1
            10    7  11 1
            11    8  12 1
            12   10  13 1
            13   11  14 1
            14    9  12 1
///
